Physician profile
Benjamin Yip
NPI 1962820605
$4,193.36
in general payments reported to CMS, 2019-2025
17 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $129 · 2023: $1,065 · 2024: $1,442 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793 · Consulting Fee: $900 · Travel and Lodging: $39.81 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.80 |
| Consulting Fee | $900.00 |
| Travel and Lodging | $39.81 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.83 | 2021-2025 | Skyrizi |
| Neptune Medical INC. | $900.00 | 2023 | |
| Medtronic, INC. | $692.65 | 2021-2025 | Endoflip, Interstim, Gi Genius |
| Janssen Biotech, INC. | $309.63 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $297.45 | 2022-2025 | Entyvio |
| Lilly USA, LLC | $184.57 | 2024-2025 | Omvoh |
| Pfizer INC. | $159.03 | 2024-2025 | |
| Celltrion USA INC. | $125.48 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $124.55 | 2021 | |
| Ardelyx, INC. | $79.05 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $64.23 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $50.04 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $49.56 | 2025 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.53 | 2024 | Xifaxan |
| Novo Nordisk INC | $29.10 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $25.38 | 2024 | Rebyota |
| Celgene Corporation | $16.28 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.